Sixteen-Week Dosage Spacing of Pfizer-BioNTech mRNA Vaccine Didn't Compromise Humoral Responses

Lengthening the interval between the two BNT162b2 doses from 4 to 16 weeks actually elicited a stronger immune response.

Although the BNT162b2 (Pfizer-BioNTech) mRNA vaccine was approved based on a regimen of two doses separated by 3–4 weeks, vaccine scarcity has driven the possible extension of this interval so that more individuals can receive at least one dose. To evaluate the impact of this adjustment, researchers assessed longitudinal humoral responses by dosing interval in SARS-CoV-2–naive and previously infected patients, with a focus on the D614G variant as well as certain variants of concern. Participants (median age, 45–51) included 26 SARS-CoV-2–naive individuals vaccinated with the 16-week (long) interval, 12 SARS-CoV-2–naive individuals vaccinated with the 4-week (short) interval, 15 previously infected individuals who received the long-interval …

Reviewing Author

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases

George Sakoulas, MD

Disclosures

Consultant/Advisory BoardParatek Pharmaceuticals; Nestle Corp.; AbbVie; Shionogi

Speaker’s BureauAllergan/AbbVie; Paratek Pharmaceuticals; Nestle Corp.

RoyaltiesUpToDate

Editorial BoardsAntimicrobial Agents and Chemotherapy; Open Forum Infectious Diseases

Sixteen-Week Dosage Spacing of Pfizer-BioNTech mRNA Vaccine Didn't Compromise Humoral Responses

Topics

Reviewing Author